Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies

BACKGROUND: The clinical trials that reported benefit of the rapalogs temsirolimus and everolimus in advanced renal cell carcinoma (RCC) were primarily conducted in patients with clear-cell histology (ccRCC). We assessed outcome with these mammalian target of rapamicin (mTOR) inhibitors in two subse...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Oncol
Hlavní autoři: Voss, M. H., Bastos, D. A., Karlo, C. A., Ajeti, A., Hakimi, A. A., Feldman, D. R., Hsieh, J. J., Molina, A. M., Patil, S., Motzer, R. J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2014
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4229900/
https://ncbi.nlm.nih.gov/pubmed/24458473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt578
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky